TBD Meeting (3193-17)

 

The Advisory Committee on Immunization Practices voted Oct. 25 to recommend a 3rd dose of measles, mumps, and rubella (MMR) vaccine for individuals at mumps risk from an outbreak.

The recommendation applies to individuals who already have been vaccinated with the usual two doses of MMR “who are identified by public health as at increased risk for mumps because of an outbreak,” according to draft text of the recommendation. This practice would “improve protection against mumps disease and related complications.”

stockce/Thinkstock

Multiple mumps outbreaks have been reported since 2015, mostly in university settings, Mona Marin, MD, CDC, said in a presentation at a meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

Young adults are at highest risk, she said.

Key evidence supporting the ACIP’s recommendation includes one recent study suggesting a 3rd dose of MMR is effective for mumps outbreak control (N Engl J Med. 2017 Sep 7; doi: 10.1056/NEJMoa1703309).

In that study, Cristina V. Cardemil, MD, of the CDC, and her colleagues looked at college students who received a 3rd MMR dose during an outbreak of at the University of Iowa in Iowa City. Almost a quarter of students (4,783 of 20,496) enrolled in the 2015-2016 academic year received a 3rd dose. Compared with two doses of MMR, students receiving three total doses had a 78% lower risk of mumps at 28 days after vaccination, investigators reported.

“These findings suggest that the campaign to administer a 3rd dose of MMR vaccine improved mumps outbreak control and that waning immunity probably contributed to propagation of the outbreak,” Dr. Cardemil and her colleagues wrote.

The vote in favor of a 3rd dose was unanimous among 15 voting members of ACIP. The committee’s recommendations must be approved by the CDC director before they are considered official recommendations.

 

The Advisory Committee on Immunization Practices voted Oct. 25 to recommend a 3rd dose of measles, mumps, and rubella (MMR) vaccine for individuals at mumps risk from an outbreak.

The recommendation applies to individuals who already have been vaccinated with the usual two doses of MMR “who are identified by public health as at increased risk for mumps because of an outbreak,” according to draft text of the recommendation. This practice would “improve protection against mumps disease and related complications.”

stockce/Thinkstock

Multiple mumps outbreaks have been reported since 2015, mostly in university settings, Mona Marin, MD, CDC, said in a presentation at a meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

Young adults are at highest risk, she said.

Key evidence supporting the ACIP’s recommendation includes one recent study suggesting a 3rd dose of MMR is effective for mumps outbreak control (N Engl J Med. 2017 Sep 7; doi: 10.1056/NEJMoa1703309).

In that study, Cristina V. Cardemil, MD, of the CDC, and her colleagues looked at college students who received a 3rd MMR dose during an outbreak of at the University of Iowa in Iowa City. Almost a quarter of students (4,783 of 20,496) enrolled in the 2015-2016 academic year received a 3rd dose. Compared with two doses of MMR, students receiving three total doses had a 78% lower risk of mumps at 28 days after vaccination, investigators reported.

“These findings suggest that the campaign to administer a 3rd dose of MMR vaccine improved mumps outbreak control and that waning immunity probably contributed to propagation of the outbreak,” Dr. Cardemil and her colleagues wrote.

The vote in favor of a 3rd dose was unanimous among 15 voting members of ACIP. The committee’s recommendations must be approved by the CDC director before they are considered official recommendations.

 

The Advisory Committee on Immunization Practices voted Oct. 25 to recommend a 3rd dose of measles, mumps, and rubella (MMR) vaccine for individuals at mumps risk from an outbreak.

The recommendation applies to individuals who already have been vaccinated with the usual two doses of MMR “who are identified by public health as at increased risk for mumps because of an outbreak,” according to draft text of the recommendation. This practice would “improve protection against mumps disease and related complications.”

stockce/Thinkstock

Multiple mumps outbreaks have been reported since 2015, mostly in university settings, Mona Marin, MD, CDC, said in a presentation at a meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

Young adults are at highest risk, she said.

Key evidence supporting the ACIP’s recommendation includes one recent study suggesting a 3rd dose of MMR is effective for mumps outbreak control (N Engl J Med. 2017 Sep 7; doi: 10.1056/NEJMoa1703309).

In that study, Cristina V. Cardemil, MD, of the CDC, and her colleagues looked at college students who received a 3rd MMR dose during an outbreak of at the University of Iowa in Iowa City. Almost a quarter of students (4,783 of 20,496) enrolled in the 2015-2016 academic year received a 3rd dose. Compared with two doses of MMR, students receiving three total doses had a 78% lower risk of mumps at 28 days after vaccination, investigators reported.

“These findings suggest that the campaign to administer a 3rd dose of MMR vaccine improved mumps outbreak control and that waning immunity probably contributed to propagation of the outbreak,” Dr. Cardemil and her colleagues wrote.

The vote in favor of a 3rd dose was unanimous among 15 voting members of ACIP. The committee’s recommendations must be approved by the CDC director before they are considered official recommendations.

 

Herpes zoster subunit vaccine (Shingrix) was preferentially recommended over zoster vaccine live (Zostavax) for preventing herpes zoster and related complications Oct. 25 at a meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

Eight committee members voted for the recommendation, and seven voted against it.

After the decision, ACIP Chair Nancy Bennett, MD, professor of medicine at the University of Rochester (N.Y.), noted that it was the “closest vote” in her term as chair of the committee, which provides advice and recommendations on vaccine-preventable diseases to the CDC.

In discussions leading up to the vote, some committee members cited potential supply issues, as well as the need for longer-term safety data, among other issues.

“I think it would be nice to see data on a larger population that is not just research-based, especially because we have very little data on ethnic minorities,” said Laura E. Riley, MD, of Harvard Medical School, Boston, who voted against the recommendation.

The vote comes several days after GlaxoSmithKline announced the Food and Drug Administration approval of Shingrix for the prevention of herpes zoster (shingles) in adults aged 50 years or older. In pooled clinical trial results, the vaccine demonstrated greater than 90% efficacy in all age groups, according to a company statement.

Shingrix is a non-live, recombinant subunit vaccine that is given in two doses, intramuscularly. Zostavax, also indicated in individuals aged 50 years or older, is a live attenuated virus vaccine.

In a related decision, ACIP voted 14-1 to recommend Shingrix for prevention of herpes zoster and related complications for immunocompetent adults aged 50 years and older.

They also voted 12-3 to recommend Shingrix to prevent herpes zoster and its complications for immunocompetent adults who previously received Zostavax.

 

Herpes zoster subunit vaccine (Shingrix) was preferentially recommended over zoster vaccine live (Zostavax) for preventing herpes zoster and related complications Oct. 25 at a meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

Eight committee members voted for the recommendation, and seven voted against it.

After the decision, ACIP Chair Nancy Bennett, MD, professor of medicine at the University of Rochester (N.Y.), noted that it was the “closest vote” in her term as chair of the committee, which provides advice and recommendations on vaccine-preventable diseases to the CDC.

In discussions leading up to the vote, some committee members cited potential supply issues, as well as the need for longer-term safety data, among other issues.

“I think it would be nice to see data on a larger population that is not just research-based, especially because we have very little data on ethnic minorities,” said Laura E. Riley, MD, of Harvard Medical School, Boston, who voted against the recommendation.

The vote comes several days after GlaxoSmithKline announced the Food and Drug Administration approval of Shingrix for the prevention of herpes zoster (shingles) in adults aged 50 years or older. In pooled clinical trial results, the vaccine demonstrated greater than 90% efficacy in all age groups, according to a company statement.

Shingrix is a non-live, recombinant subunit vaccine that is given in two doses, intramuscularly. Zostavax, also indicated in individuals aged 50 years or older, is a live attenuated virus vaccine.

In a related decision, ACIP voted 14-1 to recommend Shingrix for prevention of herpes zoster and related complications for immunocompetent adults aged 50 years and older.

They also voted 12-3 to recommend Shingrix to prevent herpes zoster and its complications for immunocompetent adults who previously received Zostavax.

 

Herpes zoster subunit vaccine (Shingrix) was preferentially recommended over zoster vaccine live (Zostavax) for preventing herpes zoster and related complications Oct. 25 at a meeting of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

Eight committee members voted for the recommendation, and seven voted against it.

After the decision, ACIP Chair Nancy Bennett, MD, professor of medicine at the University of Rochester (N.Y.), noted that it was the “closest vote” in her term as chair of the committee, which provides advice and recommendations on vaccine-preventable diseases to the CDC.

In discussions leading up to the vote, some committee members cited potential supply issues, as well as the need for longer-term safety data, among other issues.

“I think it would be nice to see data on a larger population that is not just research-based, especially because we have very little data on ethnic minorities,” said Laura E. Riley, MD, of Harvard Medical School, Boston, who voted against the recommendation.

The vote comes several days after GlaxoSmithKline announced the Food and Drug Administration approval of Shingrix for the prevention of herpes zoster (shingles) in adults aged 50 years or older. In pooled clinical trial results, the vaccine demonstrated greater than 90% efficacy in all age groups, according to a company statement.

Shingrix is a non-live, recombinant subunit vaccine that is given in two doses, intramuscularly. Zostavax, also indicated in individuals aged 50 years or older, is a live attenuated virus vaccine.

In a related decision, ACIP voted 14-1 to recommend Shingrix for prevention of herpes zoster and related complications for immunocompetent adults aged 50 years and older.

They also voted 12-3 to recommend Shingrix to prevent herpes zoster and its complications for immunocompetent adults who previously received Zostavax.